Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology. On February 2, 2026, U.S. District Judge Joshua D. Wolson denied Moderna’s request for summary judgment, saying the jury will have the choice whether Moderna’s COVID-19 vaccine, Spikevax, breached on ‘lipid nanoparticle (LNP) technology’ originally patented by Genevant Sciences and Arbutus Biopharma. Judge Wolson used a “Star Trek” metaphor, saying that even with the US Government’s “ ...

Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this biotechnology company have returned +20.7%, compared to the Zacks S&P 500 composite's -1.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Moderna falls in, has gained 21.3%. The key question now is: What could be the stock's f ...

Moderna, Inc. (NASDAQ:MRNA) is one of the noteworthy S&P 500 stocks Jim Cramer highlighted. Cramer highlighted that the company is likely to remain unprofitable for “years to come,” as he stated: Next, let’s go back to the second-best performer in the S&P for January, and that’s Moderna. That was up nearly 50%, and this was… a wild ride. After practically printing money during the pandemic thanks to its COVID vaccine, Moderna plunged 95% from its peak in 2021 to its lows last November, really gaffed a lot ...

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative companies at the forefront of biotechnology and life sciences. MRNX is designed for traders seeking magnified, short-term bullish exposure to Moderna, Inc. (NASDAQ: MRNA), a biotechnology company known for its messenger RNA (mRNA)–based medicines and vacc ...

Joining me now with more is the CEO of Mona, Stefan Bonsel, joining me right now. Stefan, welcome. Thanks so much for joining us this morning.>> Good morning, Maria. It's good to see you. Thank you for having me.>> I want to talk about this great success that you have had uh with Merc and your scientists have reported uh real breakthroughs with regard to cancer and your phase uh trials this uh this year and at the end of last year. What can you tell us, Stefan. Yes.So we're indeed very excited. We've been w ...

Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that provides messenger RNA medicines. Valued at a market cap of $17.2 billion, the company gained global prominence with its COVID-19 vaccine and continues to expand its pipeline across infectious diseases, oncology, rare diseases, and autoimmune conditions. This biotechnology company has outperformed the broader market over the past 52 weeks. Shares of MRNA have rallied 19.3% over this time frame, while the broader S&P 500 I ...

分组1 - Arbutus Biopharma Corporation (ABUS) has experienced a decline of approximately 10% in its stock price over the past month due to a patent dispute with Moderna [1] - The company is involved in the biotechnology sector, focusing on innovative drug development and unique therapeutic approaches [1] - The analyst emphasizes the importance of evaluating the scientific basis of drug candidates, competitive landscape, clinical trial design, and market opportunities while considering financial fundamentals [1]

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 trades.If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 38% with bearish.From the overall spotted trades, 4 are puts, for a total amount of $161,480 and 22, calls, for a total amount of $1,274,892.Predicted Price RangeAnalyzing the Volume and Open Interest in these con ...

报告导读： Moderna 个体化 mRNA 癌症疫苗 V940 在高危黑色素瘤中的 5 年随访结果 支持疫苗机制能提供持久免疫应答，为后续 III 期与注册推进提供了更充分的临床依据。 事件。 2026 年 1 月 21 日， Moderna 与默沙东联合披露个体化 mRNA 癌症疫苗 V940 （ mRNA-4157 ）联合 Keytruda 用于高危黑色素瘤辅助治疗的 IIb 期 5 年随访结果。该联合治疗方案在较长时间内维持了既往观察到的疗效水平，支持其能够诱导并维持相对持久的免疫应答。 核心读出数据支持疫苗机制能提供持久免疫应答。 KEYNOTE-942 研究结果显示 V940 联合 Keytruda 降低 49% 高危黑色素瘤患者复发或死亡风险，疗效 从 2 年随访时的 44% 提升至 3 年的 49% 并在 5 年随访时仍维持在 49% 。同时未发现新的安全性信号。 V940 的整体推进节奏在同类项目中较为靠前。 mRNA-4157 目前已开展 8 项 II/III 期临床研究，适应症覆盖黑色素瘤、非小细胞肺癌、膀胱癌及肾细胞癌 等多种实体瘤。其中黑色素瘤 III 期临床试验已完成入组，预计将于 ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Five years ago, Moderna, Inc. ( MRNA ) and Novavax, Inc. ( NVAX ) were two of the most talked about stocks across platforms like Seeking Alpha, social media, andEdmund Ingham is a biotech consultant. He has been co ...